- Home
- NAGE vs GHRS Comparison
NAGE vs GHRS Comparison
Compare NAGE & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAGE
- GHRS
- Stock Information
- Founded
- NAGE 1999
- GHRS 2018
- Country
- NAGE United States
- GHRS Ireland
- Employees
- NAGE N/A
- GHRS N/A
- Industry
- NAGE Medicinal Chemicals and Botanical Products
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- NAGE Health Care
- GHRS Health Care
- Exchange
- NAGE Nasdaq
- GHRS Nasdaq
- Market Cap
- NAGE 861.0M
- GHRS 874.0M
- IPO Year
- NAGE N/A
- GHRS 2021
- Fundamental
- Price
- NAGE $9.82
- GHRS $11.90
- Analyst Decision
- NAGE Strong Buy
- GHRS Strong Buy
- Analyst Count
- NAGE 3
- GHRS 8
- Target Price
- NAGE $17.00
- GHRS $30.63
- AVG Volume (30 Days)
- NAGE 803.7K
- GHRS 183.0K
- Earning Date
- NAGE 10-30-2025
- GHRS 08-07-2025
- Dividend Yield
- NAGE N/A
- GHRS N/A
- EPS Growth
- NAGE N/A
- GHRS N/A
- EPS
- NAGE 0.22
- GHRS N/A
- Revenue
- NAGE $116,303,000.00
- GHRS N/A
- Revenue This Year
- NAGE $28.46
- GHRS N/A
- Revenue Next Year
- NAGE $21.65
- GHRS N/A
- P/E Ratio
- NAGE $44.84
- GHRS N/A
- Revenue Growth
- NAGE 35.90
- GHRS N/A
- 52 Week Low
- NAGE $3.16
- GHRS $6.00
- 52 Week High
- NAGE $14.69
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- NAGE 50.03
- GHRS 34.47
- Support Level
- NAGE $9.16
- GHRS $13.71
- Resistance Level
- NAGE $9.77
- GHRS $14.59
- Average True Range (ATR)
- NAGE 0.38
- GHRS 0.75
- MACD
- NAGE 0.03
- GHRS -0.11
- Stochastic Oscillator
- NAGE 59.88
- GHRS 0.00
About NAGE Niagen Bioscience Inc. Common Stock
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.